NCT05009680进行中（未招募）1 期
GULLIVER-2 - A Single (Open-label) and Repeat Dose (Randomised, Placebo-controlled) Trial to Assess the Safety, Tolerability and Pharmacokinetics of GB1211 in Participants With Hepatic Impairment (Child Pugh B & C)
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 54
- 试验地点
- 4
- 主要终点
- Parts 3 Safety and Tolerability of GB1211
研究概览
简要总结
This study is a a single (open-label) and repeat dose (randomised, placebo controlled) trial to assess the safety, tolerability and pharmacokinetics of GB1211 (Gal-3 inhibitor) in participants with hepatic impairment (Child Pugh B and Child Pugh C)
详细描述
PART 1 A single dose, open-label safety and PK study of GB1211 administered to participants with moderate hepatic impairment (Child Pugh B) and to matched healthy participants (controls).
PART 2 A randomised, double-blind, placebo-controlled study in participants with moderate hepatic impairment (Child Pugh B). GB1211 or placebo will be administered daily for 12 weeks.
PART 3 A single dose, open-label safety and PK study of GB1211 administered to participants with severe hepatic impairment (Child Pugh C) and to healthy participants (controls).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
盲法说明
Parts 1 & 3 - Open Label, Single Dose Part 2 - Double-blind. The blinding will be maintained throughout the study.
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Main Inclusion Criteria:
- •Males or females, of any race, ≥ 18 and ≤ 75 years of age at enrolment
- •Body mass index (BMI) of ≥ 18-40 kg/m2
- •Participants with hepatic impairment:
- •PART 1 and PART 2: Moderate hepatic impairment, as defined by the Child-Pugh score (Child-Pugh B) [1] who exhibit physical signs consistent with stable hepatic impairment and free of significant medical disorders unrelated to their hepatic disorder and are on stable concomitant medication for 2 weeks prior to and for the duration of this study
- •PART 3: Severe hepatic impairment as defined by the Child-Pugh score (Child Pugh C) who exhibit physical signs consistent with stable hepatic impairment and free of significant medical disorders unrelated to their hepatic disorder and are on stable concomitant medication for 2 weeks prior to and for the duration of this study
- •Healthy participants (controls) in PART 1 and PART 3:
- •Healthy as determined by the investigator, based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac assessment
- •Match at least one of the participants with moderate or severe hepatic impairment with respect to gender, age (±10 years), and body mass index (BMI) ± 15% (ensure every participant with hepatic impairment has at least 1 matched control)
- •Women of non-childbearing potential defined as permanently sterile or postmenopausal
- •Males will agree to use contraception throughout the study and until 90-days after the Follow-up visit
- •Male participants must agree to refrain from sperm donation from the date of Randomisation (Day 1) until 90 days after the Follow up visit
- •Able to comprehend and willing to sign an ICF and to abide by the study restrictions
排除标准
- •All parts and all groups (control healthy volunteers and hepatic impairment)
- •History of an organ transplant, including a remote history of bone marrow transplant
- •History of febrile illness within 7 days prior to the first dose of study drug or participants with evidence of active infection
- •Use of any oral glucocorticoids at any dose within 30 days prior to Screening and until study completion
- •Have previously completed or withdrawn from a study investigating GB1211 and have previously received the investigational product
- •Participant who, in the opinion of the Investigator (or Designee), should not participate in this study
- •Vulnerable/institutionalised patients
- •Patients related to Principal Investigator (PI)/site staff
- •If female, the participant is of child-bearing potential
- •Participation in a clinical study involving administration of an investigational agent e.g. new chemical entity or a biological product in the past 90 days (or 5 multiples of half-life, whichever is longer) prior to dosing.
- •Medical history of cardiac disease and/or clinically significant ECG abnormalities. An abnormal ECG is defined as PR > 220 msec, QRS complex >120 msec, QTcF > 450 msec (males) and > 470msec (females), or any other morphological changes, other than nonspecific T-wave changes
- •Donation or loss of ≥ 400 mL blood or plasma less than 4 weeks prior to screening, or longer if required by local regulations
- •Positive HIV test
- •Have received live vaccine(s) within 30 days prior to Screening or who will require a vaccine(s) and until study completion
- •Use of any medications/products that may inhibit biliary excretion, e.g. bile salt chelators, mycophenolic acid, warfarin, and digoxin, within 30 days prior to Screening and until study completion
- •Use of any medications/products that may inhibit renal excretion; e.g. cimetidine, pyrimethamine, dolutegravir, probenecid, within 30 days prior to Screening and until study completion
- •Use of any medications/products that are known inhibitors of P-gp (e.g. clarithromycin, fostamatinib, quinidine, quinine) and inducers of P-gp (e.g. carbmazepine, rifampin, St. John's wort) within 30 days prior to Screening and until study completion
- •Additional exclusion criteria for matched healthy control subjects:
- •Use of any prescription or non-prescription medication (OTC), herbal medication, dietary supplements or vitamins during 30 days prior to dosing. Acetaminophen is acceptable
- •History or presence of liver disease or liver injury as indicated by an abnormal liver function profile such as AST, ALT, alkaline phosphatase, or serum bilirubin
- •A positive Hepatitis C test or a positive Hepatitis B surface antigen (HBsAg)
- •Estimated glomerular filtration rate (eGFR) < 80 mL/[min*1.73 m²] (estimated using the Modification of Diet in Renal Disease [MDRD] equation) at Screening
- •Additional exclusion criteria for hepatic impaired subjects:
- •Participants meeting any of the following exclusion criteria are not to be enrolled in the study/randomised to treatment:
- •History of any known serious disease (such as cancer, except skin basal cell carcinomas, major infection, clinically significant gastrointestinal disorder, major autoimmune disease) or other disease which in the Investigator's opinion would exclude the patient from the study
- •Estimated glomerular filtration rate (eGFR) < 40 mL/[min*1.73 m²] (estimated using the [MDRD] equation) at Screening
- •Use of any hepatotoxic drug (e.g. methotrexate, isoniazid, amiodarone) within 30 days of Screening and until study completion
- •Use or intend to use any medications/products known to alter drug absorption, metabolism, or elimination processes, including St. John's Wort, or other putatively hepatoprotective herbal remedies such as milk thistle derivatives, within 30 days prior to dosing, unless deemed acceptable by the Investigator (or Designee). Milk thistle derivates or other hepatoprotective herbal remedies are allowed if stable dose is administered 30 days before dosing
- •Use or intend to use slow release medications/products considered to still be active within 14 days prior to Randomisation, unless deemed acceptable by the Investigator (or Designee)
研究组 & 干预措施
Part 1 GB1211, Single Dose (Child Pugh B)
Experimental
GB1211 is a galectin-3 inhibitor an orally available small molecule anti-fibrotic. It is administered orally twice a day.
干预措施: GB1211 (Drug)
Part 1 GB1211 Healthy Matched Participants, Single Dose
Experimental
GB1211 is a galectin-3 inhibitor an orally available small molecule anti-fibrotic. It is administered orally twice a day.
干预措施: GB1211 (Drug)
Part 2 GB1211 Multiple Dose, Twice a day (Child Pugh B)
Experimental
GB1211 is a galectin-3 inhibitor an orally available small molecule anti-fibrotic. It is administered orally twice a day.
干预措施: GB1211 (Drug)
Part 2 Placebo, Twice a day (Child Pugh B)
Placebo Comparator
Placebo is administered twice daily
干预措施: Placebo (Drug)
Part 1 GB1211, Single Dose (Child Pugh C)
Experimental
Part 1 GB1211 Healthy Matched Participants, Single Dose
干预措施: GB1211 (Drug)
Part 3 GB1211 Healthy Matched Participants, Single Dose
Experimental
Part 1 GB1211 Healthy Matched Participants, Single Dose
干预措施: GB1211 (Drug)
结局指标
主要结局
Parts 3 Safety and Tolerability of GB1211
时间窗: 11 Days
Incidence and severity of adverse events as reported by investigators
Parts 1 Safety and Tolerability of GB1211
时间窗: 11 Days
Incidence and severity of adverse events as reported by investigators
Parts 2 Safety and Tolerability of GB1211
时间窗: 12 Weeks
Incidence and severity of adverse events as reported by investigators
次要结局
- Part 2 Collagen Production and Breakdown Biomarkers(12 Weeks)
- Part 2 Changes on liver and spleen stiffness(12 Weeks)
- Part 2 Changes in Liver Functional Capacity(12 Weeks)
研究者
研究点 (4)
Loading locations...
相似试验
已完成
1 期
Safety and Pharmacokinetic Characteristics of DKF-313Benign Prostate HyperplasiaHealthyNCT02352311Dongkook Pharmaceutical Co., Ltd.54
已完成
1 期
Compare the Pharmacokinetic Characteristics and the Safety Between Zeropix and Champix in Healthy Adult Male Subjects.Smoking, CigaretteNCT03362008Jeil Pharmaceutical Co., Ltd.31
已完成
1 期
Bioequivalence Study Between YHP1906 Tab. 5 mg and YHR1902 Tab. 5 mgHealthy VolunteersNCT04316065Yuhan Corporation30
已完成
1 期
A Clinical Trial to Evaluate the Effects of Food on the Bioavailability of CKD-397 in Healthy Male SubjectsBenign Prostatic Hypertrophy (BPH)NCT02615782Chong Kun Dang Pharmaceutical16
已完成
1 期
Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetic of CKD-501, D745, and D150 for Healthy Subjects in Fed State.Type 2 Diabetes MellitusNCT06483243Chong Kun Dang Pharmaceutical45